EP1732599A4 - Use of emmprin antagonists for the treatment of diseases associated with excessive angiogenesis - Google Patents

Use of emmprin antagonists for the treatment of diseases associated with excessive angiogenesis

Info

Publication number
EP1732599A4
EP1732599A4 EP04821758A EP04821758A EP1732599A4 EP 1732599 A4 EP1732599 A4 EP 1732599A4 EP 04821758 A EP04821758 A EP 04821758A EP 04821758 A EP04821758 A EP 04821758A EP 1732599 A4 EP1732599 A4 EP 1732599A4
Authority
EP
European Patent Office
Prior art keywords
treatment
diseases associated
excessive angiogenesis
emmprin antagonists
emmprin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04821758A
Other languages
German (de)
French (fr)
Other versions
EP1732599A1 (en
Inventor
Marian Nakada
Li Yan
Yi Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of EP1732599A1 publication Critical patent/EP1732599A1/en
Publication of EP1732599A4 publication Critical patent/EP1732599A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
EP04821758A 2004-03-25 2004-03-25 Use of emmprin antagonists for the treatment of diseases associated with excessive angiogenesis Withdrawn EP1732599A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/009151 WO2005092381A1 (en) 2004-03-25 2004-03-25 Use of emmprin antagonists for the treatment of diseases associated with excessive angiogenesis

Publications (2)

Publication Number Publication Date
EP1732599A1 EP1732599A1 (en) 2006-12-20
EP1732599A4 true EP1732599A4 (en) 2008-05-14

Family

ID=35055994

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04821758A Withdrawn EP1732599A4 (en) 2004-03-25 2004-03-25 Use of emmprin antagonists for the treatment of diseases associated with excessive angiogenesis

Country Status (6)

Country Link
EP (1) EP1732599A4 (en)
JP (1) JP2007530538A (en)
CN (1) CN1960753A (en)
AU (1) AU2004317548A1 (en)
CA (1) CA2560903A1 (en)
WO (1) WO2005092381A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4911950B2 (en) * 2005-11-07 2012-04-04 晃 伊東 Cancer invasion / metastasis inhibitor using partial peptide of MMP-1
AU2009296937B2 (en) * 2008-09-29 2015-02-12 Centocor Ortho Biotech Inc. Anti-CD147 antibodies, methods, and uses
US10709702B2 (en) * 2015-10-08 2020-07-14 Amd Therapeutics Llc Treatment of skin disorders by topical administration of VEGF inhibitors
CN108101993B (en) * 2018-01-02 2019-10-15 北京大学 A kind of anti-CD147 nano antibody, its production method and application
EP3749373A1 (en) 2018-02-07 2020-12-16 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
WO2021215836A1 (en) * 2020-04-22 2021-10-28 신풍제약주식회사 Pharmaceutical composition for treating or preventing eye diseases comprising verbenone derivative
CN114525252B (en) * 2022-03-10 2023-12-01 广州源井生物科技有限公司 Monoclonal enhancement culture medium for improving MDA-MB-231 monoclonal formation rate, culture method and application thereof
WO2023174147A1 (en) * 2022-03-18 2023-09-21 Alphelix Biotech Co., Ltd. Antibodies specifically binding to cd147 and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045031A2 (en) * 1998-03-03 1999-09-10 Abgenix, Inc. Cd147 binding molecules as therapeutics
WO2002013763A2 (en) * 2000-08-10 2002-02-21 The Picower Institute For Medical Research Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists
WO2002094875A1 (en) * 2001-05-25 2002-11-28 Zhinan Chen HAb18G/CD147, IT'S AGONIST AND APPLICATION

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508141A (en) * 2001-05-25 2005-03-31 セローノ ジェネティクス インスティテュート ソシエテ アニニム Human cDNAs and proteins and their use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045031A2 (en) * 1998-03-03 1999-09-10 Abgenix, Inc. Cd147 binding molecules as therapeutics
WO2002013763A2 (en) * 2000-08-10 2002-02-21 The Picower Institute For Medical Research Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists
WO2002094875A1 (en) * 2001-05-25 2002-11-28 Zhinan Chen HAb18G/CD147, IT'S AGONIST AND APPLICATION
EP1403284A1 (en) * 2001-05-25 2004-03-31 Chen, Zhinan HAb18G/CD147, IT'S AGONIST AND APPLICATION

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
See also references of WO2005092381A1 *
SHANG P ET AL: "Inhibitory Effects of Antisense RNA of HA18G/CD147 on Invasion of hepatocellular Carcinoma Cells in vitro", WORLD JOURNAL OF GASTROENTEROLOGY, XX, XX, vol. 9, no. 10, 2003, pages 2174 - 2177, XP003005123, ISSN: 1007-9327 *
SHANG P, QIAN A R, HU P Z, MA F C, ZHU P, CHEN Z N: "The influences of HAb18G/CD147's antagonistic peptides on angiogenesis in vivo", CHINESE PHARMACOLOGICAL BULLETIN, vol. 19, no. 3, March 2003 (2003-03-01), pages 355 - 357, XP008089960 *
ZUCKER S ET AL: "Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.", ONCOGENE 27 DEC 2000, vol. 19, no. 56, 27 December 2000 (2000-12-27), pages 6642 - 6650, XP002474900, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
CA2560903A1 (en) 2005-10-06
EP1732599A1 (en) 2006-12-20
WO2005092381A1 (en) 2005-10-06
CN1960753A (en) 2007-05-09
AU2004317548A1 (en) 2005-10-06
JP2007530538A (en) 2007-11-01

Similar Documents

Publication Publication Date Title
IL184425A0 (en) Cxcr4 antagonists for the treatment of medical disorders
ZA200608955B (en) PGD2 receptor antagonists for the treatment of inflammatory diseases
IL185422A0 (en) Pgd2 receptor antagonists for the treatment of inflammatory diseases
IL179462A0 (en) Use of the receptor gpr86
IL184934A0 (en) 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases
IL178815A0 (en) The treatment of respiratory disease
EP1789034A4 (en) Compounds with diphenoyl -structure for the treatment of immune diseases
PL1863476T3 (en) The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
SI2176252T1 (en) 2, 3-dihydrobenzoš1, 4ćdioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases
HK1127608A1 (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
EP1891065A4 (en) Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders
EP2021016A4 (en) Cxcl13 antagonists and their use for the treatment of inflammatory diseases
IL178827A0 (en) Use of reboxetine for the treatment of pain
EP1789027A4 (en) Therapeutic use of anti-tf-antigen antibody
EP1806147A4 (en) Use of immunesuppressant receptor
GB0410399D0 (en) The treatment of respiratory disease
HK1094674A1 (en) Use of antagonists of the cb1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases cb1
PL1833821T3 (en) Sulfamides as endothelin receptor antagonists for the treatment of cardiovascular diseases
EP1732599A4 (en) Use of emmprin antagonists for the treatment of diseases associated with excessive angiogenesis
HK1155670A1 (en) Therapeutic use of anti-cs1 antibodies
EP1757282A4 (en) The use of kauranes compounds in the manufacture of medicament
EP1812009A4 (en) Gaba-steroid antagonists and their use for the treatment of cns disorders
EP1819346A4 (en) Oxytocin receptor antagonists and their use for the treatment of pulmonary related diseases
GB0501655D0 (en) Therapeutic use
EP1767210A4 (en) The medical use of paeoniflorin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061023

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LT LV

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TANG, YI

Inventor name: YAN, LI

Inventor name: NAKADA, MARIAN

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CENTOCOR, INC.

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20061023

Extension state: LT

Payment date: 20061023

A4 Supplementary search report drawn up and despatched

Effective date: 20080415

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101ALN20080407BHEP

Ipc: A61P 35/00 20060101ALI20080407BHEP

Ipc: A61K 39/395 20060101AFI20051012BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080715